Liver News and Research

RSS

Clinical trial to evaluate IGF-1 in children with SHANK3 deficiency

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

25 Apr 2012

Nordion announces additional TheraSphere Phase III trial for HCC

Nordion Inc., a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced an additional randomized, multi-centre Phase III clinical trial for TheraSphere, Nordion's yttrium-90 (Y-90) glass microsphere treatment for liver cancer.

24 Apr 2012

Cancer therapy with common cold virus

Common viruses have become the latest weapon against cancer. There is the case of the eight-year-old African boy diagnosed with Burkitt's lymphoma at a Ugandan health clinic. He was exposed to the measles virus and in the next few weeks his tumour regressed completely and he entered remission. But only relatively recently have scientists clinically examined the interaction between viruses and cancers in the growing area of oncolytic virotherapy.

24 Apr 2012

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

Liver may be the key to weight regulation: Study

A team of Australian researchers have found that the liver could hold the key to treating obesity. They found that the liver plays a major role in regulating weight by communicating with the brain. The study will be published in the Journal Diabetes.

23 Apr 2012

Vietnam asks for international help to tackle mystery skin disease

Vietnam has asked for international aid to get to the bottom of a mystery skin infection that has already killed 19 people. More than 170 people in the country's central province of Quang Ngai have reported symptoms reports say.

23 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

ActiViews CT-Guide Needle Guidance System for liver interventions receives FDA 510(k) clearance

ActiViews, Inc, a company pioneering the development of simple, accurate, and cost-effective surgical navigation solutions, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its flagship product, CT-Guide Needle Guidance System, for liver interventions.

23 Apr 2012

Soy protein may reduce fat accumulation, triglycerides in the livers of obese persons

University of Illinois scientists report that soy protein may significantly reduce fat accumulation and triglycerides in the livers of obese persons. And they've discovered why it happens: soy restores partial function of that organ's key signaling pathway.

23 Apr 2012

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.

21 Apr 2012

Liver can directly talk to the brain to control amount of food we eat

Dr Barbara Fam from the University's Molecular Obesity Laboratory group at Austin Health with Associate Professor Sof Andrikopoulos have discovered that the liver can directly talk to the brain to control the amount of food we eat.

21 Apr 2012

Sequana Medical's ALFApump System safe and effective in managing ascites

Sequana Medical announced that initial results from the PIONEER Clinical Study of its ALFApump System were presented today at the 47th annual European Association for Study of the Liver Meeting in Barcelona.

21 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

New data from descriptive sub-analysis of patients with compensated liver cirrhosis

New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.

20 Apr 2012

Study determines importance of bacterial infections in cirrhosis

A South African study presented today determines the importance of bacterial infections, which commonly occur in cirrhosis and can alter the natural history of the condition, possibly leading to loss of liver function and decompensation. It is now recognised that many infections in cirrhotic patients result from bacterial translocation (BT) from the intestine.

20 Apr 2012

Potential for gallbladder tissue as source for multipotential stem cells

A new study presented today at the International Liver Congress- 2012 indicates the potential for gallbladder tissue (which is routinely discarded from organ donors and surgical interventions) to be a highly available candidate source for multipotential stem cells.

20 Apr 2012

New data provides hope for HCV non-responders

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2012 provides hope for previously difficult to treat hepatitis C (HCV) patient populations.

20 Apr 2012

New evidence helps explain additional health benefits of aspirin

New evidence is helping explain additional health benefits of aspirin. Researchers in Canada, Scotland and Australia have discovered that salicylate, the active ingredient in aspirin, directly increases the activity of the protein AMPK (AMP-activated protein kinase), a key player in regulating cell growth and metabolism. AMPK which is considered a cellular fuel-gauge is switched on by exercise and the commonly used anti-diabetic medication metformin.

20 Apr 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012